Zanamivir: an inhaled route can be the reason to reject a plan

The label says Relenza is not recommended for treatment or prophylaxis in people with underlying airway disease such as asthma or COPD. Serious bronchospasm, including fatal cases, has been reported in patients with and without prior airway disease. An inhaled route should not be assumed to be gentler for every respiratory patient.

Recover the actual diagnosis and respiratory status. A patient with acute dyspnea needs assessment, not a device-technique workaround. If bronchospasm or declining respiratory function develops during Relenza use, the label directs discontinuation and immediate treatment, with hospitalization potentially required.

The inhalation powder must be administered only with the provided Diskhaler. The label describes reports involving a solution made from Relenza powder and delivered through nebulization or mechanical ventilation, including a fatal equipment-obstruction report involving lactose. The powder is not a recipe for a liquid preparation.

Difficulty using the device is a reason to reassess suitability and the treatment plan. It is not permission to dissolve the powder, place it in a nebulizer or improvise an enteric route. Product identity includes the formulation and device, not only the generic name on a chart.

The label contraindicates Relenza in a history of allergic reaction to any ingredient, including milk proteins. Its powder contains lactose with milk proteins. Lactose intolerance and a severe milk-protein allergy are not equivalent clinical histories, so do not substitute one term for the other.

Ask what reaction occurred and to which substance. A history of gastrointestinal intolerance does not establish the same immune reaction, while a documented serious milk-protein reaction should not be dismissed as a dislike of dairy. Use the actual label and clinical allergy assessment rather than clearing the product from its active ingredient alone.

When airway disease, allergy or inability to use the device makes a proposed plan unsuitable, the next step is a clinician-supported alternative with the patient's age, severity and other conditions considered. The fact that another influenza antiviral exists does not supply its dose or suitability.

For an exam case, identify which feature makes the proposed inhaled plan need review. Do not answer only with a technique checklist when the patient is in the label's not-recommended population. In practice, acute symptoms and the treatment-priority category determine urgency alongside formulation selection.

Try it before reading the answer

Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.

Continue learning